In a new guest column appearing in the latest edition of Clinical Leader, Precision for Value’s Jeremy Schafer argues for the inclusion of value measurements into oncology trials, outlining the potential end points as well as the significant rewards that can be gained after product launch due to the enhanced value proposition.
To read the complete article, please click here.